02:18 PM EDT, 03/21/2024 (MT Newswires) -- Eledon Pharmaceuticals ( ELDN ) said Thursday its tegoprubart was used as a part of the immunosuppressive treatment regimen after a kidney transplant from a genetically modified pig to a 62-year-old man living with end-stage kidney disease.

The company previously said that tegoprubart, as part of an immunosuppressive regimen, successfully prevented rejection based on results from 11 participants enrolled in its phase 1b kidney transplantation study.

Eledon's phase 2 study of tegoprubart compared with tacrolimus for the prevention of rejection in kidney transplantation plans to complete enrollment at the end of 2024.

Shares of the company rose 3.7% in recent trading Thursday.

Price: 1.73, Change: +0.06, Percent Change: +3.72